氯雷他定治疗面部慢性湿疹临床疗效及安全性分析  

Efficacy and Safety of Loratadine Treating Facial Chronic Eczema

作　　者：雷雅丽[1] 

机构地区：[1]山西省宝鸡市解放军第三医院,宝鸡721004

出　　处：《中国中西医结合皮肤性病学杂志》2016年第2期106-108,共3页Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine

摘　　要：目的观察分析氯雷他定治疗面部慢性湿疹临床疗效及安全性,为临床提供治疗方案参考。方法选择从2013年3月—2015年3月收治面部慢性湿疹患者共89例。随机将患者分为A组和B组,其中A组患者单纯氯雷他定治疗;B组患者则采用盐酸非索非那定治疗。对2组患者临床面部湿疹评分及疗效进行对比。结果 2组患者治疗1周后A组患者的临床症状评分明显要比B组患者低,2组数据对比差异有统计学意义(P<0.05);治疗2周后A组患者的临床面部湿疹评分与B组患者对比差异无统计学意义(P>0.05)。A组治疗有效率为100.0%,B组患者有2例治疗失败患者,治疗有效率为95.5%,2组数据对比差异有统计学意义(P<0.05)。其中A组的治愈率为51.1%,明显高于B组的34.1%,2组数据对比差异有统计学意义(P<0.05)。结论氯雷他定能够有效治疗面部慢性湿疹,并且起效相对较快而安全性相对较好。Objective In order to observe and analyze the efficacy and safety of loratadine in treating facial chronic eczema in order to offer reference of therapeutic scheme. Methods Eighty-nine patients with facial chronic eczema accepted from Mar. 2013 to Mar. 2015 were selected and randomly divided into group A and group B. Group A was treated with loraradine,and group B was treated with fexofenadine hydrochloride. Then the facial eczema score and clinical efficacy were compared.Results Clinical symptom score one week after therapy of group A was lower than group B with statistical significance（P〈0.05）. The facial eczema score two weeks after therapy of two groups had no obvious difference（P〈0.05）. The treatment effectiveness of group A was 100.0%, which was obviously higher than group B with the efficacy of 95.5%（P〈0.05）. The cure rate of group A（51.1%） was much higher than group B（34.1%） with statistical significance（P〈0.05）. Conclusion Loratadine is safe and effective in treating facial chronic eczema.

关 键 词：氯雷他定 面部 慢性湿疹 疗效 安全性 

分 类 号：R758.23[医药卫生—皮肤病学与性病学]